This article provides historical background and current research involving the use of
bevacizumab for the treatment of recurrent glioblastoma. Although bevacizumab, approved
by the Food and Drug Administration, prolongs glioblastoma progression free survivial,
decreases tumor vascularization, and reduces permeability of vessels, it does not seem to
prolong overall survival. Despite slowed primary tumor progression, bevacizumab treatment
may facilitate transformation to a more invasive phenotype. Adaptive responses, which make …